

Kim De Keersmaecker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5946800/publications.pdf>

Version: 2024-02-01

94
papers

4,927
citations

87888

38
h-index

95266

68
g-index

98
all docs

98
docs citations

98
times ranked

7755
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2012, 18, 298-302. | 30.7 | 453 |
| 2 | Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 186-190. | 21.4 | 365 |
| 3 | Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. <i>Nature Cell Biology</i> , 2010, 12, 372-379. | 10.3 | 316 |
| 4 | The genetics and molecular biology of T-ALL. <i>Blood</i> , 2017, 129, 1113-1123. | 1.4 | 273 |
| 5 | Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2007, 39, 593-595. | 21.4 | 252 |
| 6 | Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. <i>Nature Immunology</i> , 2010, 11, 717-724. | 14.5 | 187 |
| 7 | Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2010, 42, 530-535. | 21.4 | 162 |
| 8 | The TLX1 oncogene drives aneuploidy in T cell transformation. <i>Nature Medicine</i> , 2010, 16, 1321-1327. | 30.7 | 139 |
| 9 | Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. <i>Nature Medicine</i> , 2012, 18, 436-440. | 30.7 | 138 |
| 10 | Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2013, 122, 74-82. | 1.4 | 133 |
| 11 | How Ribosomes Translate Cancer. <i>Cancer Discovery</i> , 2017, 7, 1069-1087. | 9.4 | 131 |
| 12 | Loss or Inhibition of Stromal-Derived PIGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. <i>Cancer Cell</i> , 2011, 19, 740-753. | 16.8 | 124 |
| 13 | Hallmarks of ribosomopathies. <i>Nucleic Acids Research</i> , 2020, 48, 1013-1028. | 14.5 | 122 |
| 14 | Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). <i>Blood</i> , 2005, 105, 4849-4852. | 1.4 | 119 |
| 15 | Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. <i>PLoS Genetics</i> , 2013, 9, e1003997. | 3.5 | 110 |
| 16 | Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 4476-4479. | 1.4 | 96 |
| 17 | The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types. <i>Oncotarget</i> , 2017, 8, 14462-14478. | 1.8 | 92 |
| 18 | Targeting Nonclassical Oncogenes for Therapy in T-ALL. <i>Cancer Cell</i> , 2012, 21, 459-472. | 16.8 | 84 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2005, 90, 1116-27. | 3.5 | 84 |
| 20 | Ribosomopathies and the paradox of cellular hypo- to hyperproliferation. <i>Blood</i> , 2015, 125, 1377-1382. | 1.4 | 83 |
| 21 | The ins and outs of serine and glycine metabolism in cancer. <i>Nature Metabolism</i> , 2021, 3, 131-141. | 11.9 | 82 |
| 22 | In vitro validation of \hat{A} -secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2008, 93, 533-542. | 3.5 | 77 |
| 23 | Bypass of the pre-60S ribosomal quality control as a pathway to oncogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5640-5645. | 7.1 | 71 |
| 24 | Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 1358-1369. | 7.2 | 66 |
| 25 | Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2009, 23, 125-133. | 7.2 | 65 |
| 26 | Cancer Biogenesis in Ribosomopathies. <i>Cells</i> , 2019, 8, 229. | 4.1 | 64 |
| 27 | Chronic myeloproliferative disorders: a tyrosine kinase tale. <i>Leukemia</i> , 2006, 20, 200-205. | 7.2 | 63 |
| 28 | High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes. <i>PLoS ONE</i> , 2012, 7, e38463. | 2.5 | 58 |
| 29 | The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. <i>Leukemia</i> , 2018, 32, 809-819. | 7.2 | 57 |
| 30 | Impact of weak Fermi-level pinning on the correct interpretation of III-V MOS C-V and G-V characteristics. <i>Microelectronic Engineering</i> , 2007, 84, 2146-2149. | 2.4 | 55 |
| 31 | Kinase Activation and Transformation by NUP214-ABL1 Is Dependent on the Context of the Nuclear Pore. <i>Molecular Cell</i> , 2008, 31, 134-142. | 9.7 | 55 |
| 32 | Synergistic antileukemic therapies in <i>NOTCH1</i> -induced T-ALL. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2006-2011. | 7.1 | 50 |
| 33 | The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. <i>Leukemia</i> , 2019, 33, 319-332. | 7.2 | 50 |
| 34 | RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. <i>Leukemia</i> , 2017, 31, 1706-1714. | 7.2 | 49 |
| 35 | Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCR β -HOXA rearrangement: a study of the Groupe Francophone de Cytog \hat{A} matologique. <i>Leukemia</i> , 2007, 21, 121-128. | 7.2 | 43 |
| 36 | Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells. <i>Nature Communications</i> , 2019, 10, 2542. | 12.8 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 801-811. | 1.4 | 43 |
| 38 | Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. <i>Leukemia</i> , 2008, 22, 2208-2216. | 7.2 | 42 |
| 39 | NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins. <i>Haematologica</i> , 2014, 99, 85-93. | 3.5 | 38 |
| 40 | Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis in Addicted Breast Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 50-63. | 4.1 | 31 |
| 41 | Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma. <i>Haematologica</i> , 2017, 102, e317-e320. | 3.5 | 27 |
| 42 | Ribosomal rRNA analysis in the diagnosis of Diamond-Blackfan Anaemia. <i>British Journal of Haematology</i> , 2016, 172, 782-785. | 2.5 | 24 |
| 43 | An activating intragenic deletion in NOTCH1 in human T-ALL. <i>Blood</i> , 2012, 119, 5211-5214. | 1.4 | 22 |
| 44 | Ribosomal Lesions Promote Oncogenic Mutagenesis. <i>Cancer Research</i> , 2019, 79, 320-327. | 0.9 | 22 |
| 45 | Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2019, 3, e310. | 2.7 | 19 |
| 46 | The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 5747-5758. | 7.0 | 19 |
| 47 | 14q32 rearrangements deregulating <i>BCL11B</i> mark a distinct subgroup of T and myeloid immature acute leukemia. <i>Blood</i> , 2021, 138, 773-784. | 1.4 | 19 |
| 48 | SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. <i>Cell Reports</i> , 2020, 31, 107640. | 6.4 | 16 |
| 49 | Large expert-curated database for benchmarking document similarity detection in biomedical literature search. <i>Database: the Journal of Biological Databases and Curation</i> , 2019, 2019, . | 3.0 | 15 |
| 50 | <i>HEATR3</i> variants impair nuclear import of uL18 (RPL5) and drive Diamond-Blackfan anemia. <i>Blood</i> , 2022, 139, 3111-3126. | 1.4 | 15 |
| 51 | TLX1-Induced T-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2011, 17, 6381-6386. | 7.0 | 14 |
| 52 | Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. <i>Blood</i> , 2012, 119, 3864-3866. | 1.4 | 12 |
| 53 | VEGFC Antibody Therapy Drives Differentiation of AML. <i>Cancer Research</i> , 2018, 78, 5940-5948. | 0.9 | 12 |
| 54 | JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines. <i>Haematologica</i> , 2009, 94, 435-437. | 3.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia. <i>Leukemia</i> , 2006, 20, 2202-2204. | 7.2 | 10 |
| 56 | Codon bias analyses on thyroid carcinoma genes. <i>Minerva Endocrinologica</i> , 2021, 45, 295-305. | 1.8 | 10 |
| 57 | PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 97. | 17.0 | 10 |
| 58 | Development of a Myeloproliferative Disease or a T Cell Lymphoblastic Leukemia in a Murine Bone Marrow Transplant Model of NUP214-ABL1.. <i>Blood</i> , 2006, 108, 618-618. | 1.4 | 10 |
| 59 | T-ALL: ALL a matter of Translation?. <i>Haematologica</i> , 2015, 100, 293-295. | 3.5 | 8 |
| 60 | The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.. <i>Blood</i> , 2009, 114, 142-142. | 1.4 | 8 |
| 61 | Ribosomal proteins: a novel class of oncogenic drivers. <i>Oncotarget</i> , 2017, 8, 89427-89428. | 1.8 | 8 |
| 62 | Involvement of the NOTCH1 and NOTCH2 Genes in B-Cell Lymphomagenesis.. <i>Blood</i> , 2006, 108, 2072-2072. | 1.4 | 8 |
| 63 | Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing. <i>HemaSphere</i> , 2022, 6, e700. | 2.7 | 8 |
| 64 | Rise of the specialized onco-ribosomes. <i>Oncotarget</i> , 2018, 9, 35205-35206. | 1.8 | 7 |
| 65 | Bloody Mysteries of Ribosomes. <i>HemaSphere</i> , 2018, 2, e95. | 2.7 | 5 |
| 66 | Oncogenic Properties of the T-ALL Associated EML1-ABL1 and NUP214-ABL1 Fusion Proteins.. <i>Blood</i> , 2006, 108, 1830-1830. | 1.4 | 5 |
| 67 | The other Achilles' heel of BCR-ABL1. <i>Haematologica</i> , 2012, 97, 2-2. | 3.5 | 4 |
| 68 | A novel mouse model provides insights into the neutropenia associated with the ribosomopathy Shwachman-Diamond syndrome. <i>Haematologica</i> , 2015, 100, 1237-1239. | 3.5 | 4 |
| 69 | EML1-ABL1 Is Activated by Coiled-Coil-Mediated Oligomerization and Induces T-Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model. <i>HemaSphere</i> , 2018, 2, e32. | 2.7 | 2 |
| 70 | ABL1 fusions in T-cell acute lymphoblastic leukemia. <i>Verhandelingen - Koninklijke Academie Voor Geneeskunde Van België</i> , 2008, 70, 245-55. | 0.2 | 2 |
| 71 | T-Cell acute lymphoblastic leukemia with a ϕ -pinch of BCR-ABL1. <i>Leukemia and Lymphoma</i> , 2009, 50, 321-322. | 1.3 | 1 |
| 72 | Therapeutic Utility of PI3K β Inhibition in Leukemogenesis and Tumor Cell Survival. <i>Blood</i> , 2012, 120, 1492-1492. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Novel insights on TLX1 function in T-ALL pave the way towards differentiation therapy. Haematologica, 2012, 97, 795-795. | 3.5 | 0 |
| 74 | Analysis of Gene Expression Data of RPL10 Mutant T-Cell Leukemia by SEMsubPA. , 2018, , . | | 0 |
| 75 | PF165 THE XPO1 INHIBITOR KPTâ€8602 WORKS SYNERGISTIC WITH DEXAMETHASONE TO INHIBIT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS. HemaSphere, 2019, 3, 34-35. | 2.7 | 0 |
| 76 | PF159 COMBINATION OF SELECTIVE GAMMAâ€SECRETASE INHIBITOR MRKâ€560 WITH OTHER TARGETED THERAPY IS AN EFFECTIVE AND SAFE TREATMENT FOR Tâ€ALL. HemaSphere, 2019, 3, 31. | 2.7 | 0 |
| 77 | Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation. Leukemia, 2020, 34, 651-655. | 7.2 | 0 |
| 78 | Array-CGH Analysis of T-ALL Patients and Cell Lines.. Blood, 2006, 108, 4469-4469. | 1.4 | 0 |
| 79 | Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 141-141. | 1.4 | 0 |
| 80 | Oncogenic Transcriptional Programs Controlled by TLX1/HOX11 and TLX3/HOX11L2 in T-ALL.. Blood, 2009, 114, 676-676. | 1.4 | 0 |
| 81 | Precursor T-Cell Neoplasms. Molecular Pathology Library, 2010, , 329-346. | 0.1 | 0 |
| 82 | BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471. | 1.4 | 0 |
| 83 | Whole Transcriptome Sequencing In Refractory T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 350-350. | 1.4 | 0 |
| 84 | RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response. Blood, 2015, 126, 2969-2969. | 1.4 | 0 |
| 85 | Synergistic Targeting of Protein Translation and Inhibition of NOTCH Signaling in T-ALL. Blood, 2015, 126, 3719-3719. | 1.4 | 0 |
| 86 | Abstract 1546: Contribution of heterozygous loss of ribosomal protein L5 as general tumor suppressor in cancer. , 2017, , . | | 0 |
| 87 | Abstract 3034: A programmed ribosomal frameshifting defect potentiates the transforming activity of the JAK2-V617F mutation. , 2017, , . | | 0 |
| 88 | Proteasome Inhibition By Carfilzomib Impairs Terminal Erythroid Maturation and Causes Reticulocytosis in Patients with Multiple Myeloma. Blood, 2018, 132, 1036-1036. | 1.4 | 0 |
| 89 | PF570 CARFILZOMIB TREATMENT CAUSES RETICULOCYTOSIS BY IMPAIRING TERMINAL ERYTHROID MATURATION IN PATIENTS WITH MULTIPLE MYELOMA. HemaSphere, 2019, 3, 237. | 2.7 | 0 |
| 90 | Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing. Blood, 2019, 134, 2749-2749. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Abstract 1789: Repurposing the anti-depressant sertraline to target serine/glycine synthesis addicted cancer. , 2020, , . | | 0 |
| 92 | Loss of the Base Excision Repair Gene <i>Apex1</i> Leads to Dysfunctional Adult Hematopoietic Stem and Progenitor Cells. Blood, 2021, 138, 3267-3267. | 1.4 | 0 |
| 93 | Opportunities of Genome Imaging for Genetic Diagnosis in Acute Lymphoblastic Leukemia. Blood, 2020, 136, 10-11. | 1.4 | 0 |
| 94 | Exploitation of the ribosomal protein L10 R98S mutation to enhance recombinant protein production in mammalian cells. Engineering in Life Sciences, 2022, 22, 100-114. | 3.6 | 0 |